← All stocks

CRESCENT BIOPHARMA, INC.

CBIO Net buying
CIK 0001253689 #2943 in the set updated 17 Sep 2026
Bought (120 mo)
$46.91M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$16.45M
$1.23M on a plan · $1.36M straight out of an exercise
Sold at will
$13.86M
34 of 51 sales
Net
+$30.47M
+$33.05M against sales at will

By person

29 insiders · 98 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Fairmount Funds Management LLC entity
Director
$30.61M (2)
+$30.61M
3,601,316
$52.22M
+159.5%
SANDELL SCOTT D
10% owner
$13.04M (14)
−$13.04M
11,326,237
$164.23M
−24.2%
BVF PARTNERS L P/IL entity
10% owner
$11.17M (9)
+$11.17M
62,383
$904.55K
Invus Public Equities, L.P.
10% owner
$3.95M (8)
$488.75K (9)
+$3.46M
6,317,565
$91.60M
−3.7%
Brumm Joshua T
Chief Executive Officer
$761.07K (1) scheduled
−$761.07K
281,212
$4.08M
+4.8%
Rock Edwin
Chief Medical Officer
$725.58K (7)
+$725.58K
680,403
$9.87M
McNeill Jonathan
President and COO
$369.68K (1) scheduled
−$369.68K
139,158
$2.02M
+3.7%
Hahn Brian M.
SVP Finance, CFO
$25.53K (2)
$359.38K (3) scheduled
−$333.84K
70,643
$1.02M
+401.5%
King Rachel K.
Director
$329.13K (1) scheduled
−$329.13K
690,336
$10.01M
+88.4%
Magnani John L.
SVP of Research, CSO
$52.70K (1)
$353.73K (4)
−$301.03K
370,923
$5.38M
+289.5%
JUNIUS DANIEL M
Director
$214.05K (5)
+$214.05K
98,459
$1.43M
BARRETT M JAMES
Director
$169.89K (2) scheduled
−$169.89K
9,089,041
$131.79M
+5.9%
BARRIS PETER J
10% owner
$169.89K (2) scheduled
−$169.89K
9,089,041
$131.79M
+5.9%
NEW ENTERPRISE ASSOCIATES 10 L P entity
10% owner
$169.89K (2) scheduled
−$169.89K
4,995,664
$72.44M
+11.2%
Thackray Helen M.
SVP Clinical Development, CMO
$139.44K (6)
−$139.44K
183,115
$2.66M
+14.0%
Andrews Patricia S
Director
$82.00K (1)
+$82.00K
58,608
$849.82K
Semerjian Harout
Chief Executive Officer
$32.25K (1)
+$32.25K
25,000
$362.50K
PEARSON TIMOTHY R
Director
$25.03K (1)
+$25.03K
24,650
$357.43K
Pinkas Jan
Chief Scientific Officer
$23.17K (1) scheduled
−$23.17K
22,239
$322.47K
+2,080%
Im Ellie Eunkyung
Chief Medical Officer
$21.93K (1) scheduled
−$21.93K
22,069
$320.00K
+1,009%
Bispham Barbara Harlin
See Remarks
$21.91K (1) scheduled
−$21.91K
19,330
$280.29K
+809.2%
Johnson Bruce S
SVP & Chief Commercial Officer
$21.20K (1)
+$21.20K
138,980
$2.02M
+10.8%
Scalzo Richard William
Chief Financial Officer
$20.00K (1) scheduled
−$20.00K
20,298
$294.32K
+921.0%
Lynch Ryan
See Remarks
$8.37K (1) scheduled
−$8.37K
13,871
$201.13K
+608.4%
Girard Armand
SVP, Chief Business Officer
$6.83K (1)
$2.55K (1)
+$4.28K
29,161
$422.83K
Doughty Christopher Grant
Chief Business Officer
62,194
$901.81K
+57.5%
Koenig Scott
Director
36,750
$532.88K
Goldberg Mark Alan
Director
36,325
$526.71K
+216.0%
Jackson Scott Thomas
Director
5,250
$76.13K

No percentages here. This company's share count has moved by a factor of 4.6 over the window, from 13,892,516 to 64,532,091 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Koenig Scott
1 Jun 2023
Director
Exercised, kept
21,000
$0.60
$12.60K
Koenig Scott
27 Jan 2023
Director
Exercised, kept
10,500
$2.55
$26.78K
Hahn Brian M.
16 Dec 2020
SVP Finance, CFO
Exercised, kept
5,260
$1.12
$5.89K
Magnani John L.
6 Jan 2020
SVP of Research, CSO
Exercised, kept
106,983
$1.12
$119.82K
Magnani John L.
20 Dec 2019
SVP of Research, CSO
Exercised, kept
106,984
$1.12
$119.82K
King Rachel K.
6 Aug 2019
President, CEO
Exercised, kept
166,759
$1.12
$186.77K
Magnani John L.
23 May 2018
SVP of Research, CSO
Exercised, kept
1,491
$0.33
$492.03
Magnani John L.
10 May 2017
SVP of Research, CSO
Exercised, kept
8,928
$1.12
$10.00K

What was left out

Form 4 filings counted 184
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 17
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 10
Sales at will 34
Transactions with no price 0
Shares from compensation/vesting 4,400,797
Sales filed before the plan box existed 24
History held since 4 Oct 2016